- Report
- May 2024
- 136 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- May 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- March 2024
- 96 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- February 2023
- 92 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Drug Pipelines
- February 2022
- 60 Pages
Global
From €9539EUR$9,995USD£7,992GBP
- Report
- August 2022
United States
From €1851EUR$1,940USD£1,551GBP
- Report
- August 2022
Global
From €754EUR$790USD£632GBP
- Report
- August 2021
Global
From €3808EUR$3,990USD£3,191GBP
- Report
- August 2024
- 90 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- June 2022
- 126 Pages
Global
From €1909EUR$2,000USD£1,599GBP
Fragile X Syndrome (FXS) is a genetic disorder that is the most common inherited cause of intellectual disability and autism. It is caused by a mutation in the FMR1 gene, which leads to an absence of the FMRP protein. As a result, individuals with FXS experience a range of cognitive, behavioral, and physical symptoms.
The Fragile X Syndrome Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs that are used to treat the symptoms of FXS, such as cognitive impairment, anxiety, and hyperactivity. These drugs are typically prescribed by neurologists and psychiatrists, and may include antipsychotics, antidepressants, and stimulants.
The Fragile X Syndrome Drug market is a growing field, as more research is conducted into the disorder and its treatment. Companies in this market include Shire, Novartis, and Ovid Therapeutics. Show Less Read more